Background: The initial results of imatinib in Ph-positive CML in chronic phase post IFN failure were positive with a median follow up times of 17 months. The major cytogenetic (CG) response rate (Ph ...

Design and first interim analysis of a randomized phase III trial comparing imatinib versus imatinib (IM) based combination therapies in newly diagnosed chronic myelogenous leukemia patients in ...

In Canada, Scemblix ® was previously approved for the treatment of adult patients with Ph+ CML-CP previously treated with two or more TKIs. Newly diagnosed patients will now have access to a treatment ...

A study from a major cancer center collected data on 2857 patients with Ph+ CML, most of whom were White and middle-aged. Ten-year overall survival for patients with Ph+ CML treated since 2000 was ...

Poitiers, Sunday 5th December 2004 -- CHU in Poitiers, France, today announced results of a study showing that newly diagnosed patients with a certain form of leukemia who are treated early with ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Dr Radich is a ...

ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to ...

Articles published in this focus collection were selected from recent issues of Leukemia. They highlight new developments in our understanding and management of persons with CML. CML was the first ...

Panel A shows the timeline 1-8 from the discovery of the t(9;22) translocation to the development of imatinib (previously called STI571), the first tyrosine kinase inhibitor. Panel B shows the ...

Takeda picked up Iclusig as part of a $5.2 billion deal with Ariad with the promise that it could make some more out of the blood cancer drug. So far, so good. On Thursday, the Japanese company ...